Zenrelia is a drug owned by ELANCO US INC. It is protected by 2 US drug patents filed in 2040. All patents are active. Details of Zenrelia’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US11548895 | 22 Apr, 2040 | Active |
Exclusivity Information
Zenrelia holds 1 exclusivity out of which 1 has expired. Details of Zenrelia's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Sep 19, 2024 |
About Zenrelia
Zenrelia is a drug
owned by ELANCO US INC.
Zenrelia uses
Ilunocitinib as the active
ingredient.
Active Ingredient:
Zenrelia uses
Ilunocitinib as the active ingredient.
Check out other Drugs and Companies using
Ilunocitinib ingredient.